Login to Your Account



Regeneron's robust Eylea sales lift outlook as well as shares

By Michael Fitzhugh
Staff Writer

Tuesday, August 4, 2015

Surging global sales of Regeneron Pharmaceuticals Inc.'s blockbuster Eylea drove company revenues 50 percent higher during the second quarter, leading it to raise full-year guidance.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription